Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi AnemiaBusiness Wire • 26 days ago
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Share to Feed
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM Research Report) and Rocket Pharmaceuticals...
Rocket Pharmaceuticals (RCKT) has shared an announcement. Rocket Pharmaceuticals, Inc. has appointed Aaron Ondrey as their new Chief Financial Offi...
This is a signal that RCKT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today...
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT Get Free Report) Director Gotham Makker sold 274,000 shares of the stock in a transaction dated Thursday, March 21st. The stock was sold at an...
This indicator may be signaling RCKT's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...
This is a signal that RCKT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT Get Free Report) insider John Militello sold 10,000 shares of the stock in a transaction dated Thursday, February 29th. The shares were sold at an...
This is a Bearish indicator signaling RCKT's price could decline from here. Traders may explore shorting the stock or put options...